CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 644 enrolled
Drug / intervention
BNT162b2 (Omi XBB.1.5)/RIV +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06237049
NCT06237049Phase 2Completed
CompareCT.gov

A Phase 1/2 Randomized Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA COVID-19 Vaccine and a Recombinant Influenza Vaccine Administered as a Single Injection in Healthy Adults 50 Years of Age or Older

Pfizer·interventional·Posted Feb 1, 2024·Updated Sep 30, 2025

In Brief

A Phase 2 clinical trial evaluating BNT162b2 (Omi XBB.1.5)/RIV, BNT162b2 (Omi XBB.1.5), and 2 other interventions for Influenza, Human and 2 related conditions. Completed, enrolled 644 participants across 30 sites.

Detailed Summary

The purpose of this clinical trial is to see if combining a licensed COVID-19 vaccine and a licensed influenza vaccine into a single shot is safe and can help produce antibodies to defend the body against both SARS-CoV-2 (the virus that causes COVID-19) and influenza. Participants enrolled in this trial will be healthy adults, 50 years of age or older.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza, Human, SARS-CoV-2 Infection, COVID-19
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202420252026
First PostedFeb 1, 2024
Enrollment StartJan 31, 2024
Primary CompletionSep 13, 2024
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 2.4 years ago

Interventions

BNT162b2 (Omi XBB.1.5)/RIVbiological

Combination of BNT162b2 (Omi XBB.1.5) and RIV

BNT162b2 (Omi XBB.1.5)biological

Licensed COVID-19 vaccine

RIVbiological

Licensed recombinant influenza vaccine

Normal saline placeboother

Normal saline (solution for injection)